Category 8- Best Drug Pipeline

Open to: Pharmaceutical companies

This award strives to recognise the importance of R&D to the growth of the pharma industry. The awards will be looking at the most promising batch of investigational drugs (including vaccines) that is undergoing clinical development. Voters will be looking at not just the size of the drug pipeline, but also for the quality, innovation and its potential market value.

All investigational products, including drugs, small molecules, proteins and vaccines (from Phase I clinical trials to registration) by the applicant at the time of entry are eligible to be included in the pipeline. Entrants must indicate details any joint-venture or licensing deals for any of the clinical candidates. Should any product be dropped subsequently from development, it will be removed from the entry.

Please tabulate all the drug candidates included in the company's pipeline according to the phase of development, including:

  • Their names (Code, Trade and Generic as applicable)
  • Mechanisms of Action
  • Therapeutic Indication

Company Pipeline
Phase I
Product Name Mechanism of Action Therapeutic Indication
Phase II
Product Name Mechanism of Action Therapeutic Indication
Phase III
Product Name Mechanism of Action Therapeutic Indication

Companies will be judged on the following criteria:

  • The development phase the product is currently at
  • The range of therapeutic areas that the product covers
  • The market potential of the pipeline
  • The importance of the pipeline in matching unmet medical needs